BACKGROUND: Limited data exists on the long-term outcomes of patients with obscure gastrointestinal bleeding (OGIB) following single-balloon enteroscopy (SBE). AIM: To examine the long-term outcomes of patients undergoing SBE for OGIB. METHODS: Consecutive patients undergoing SBE for OGIB at a tertiary care center between 2008 and 2010 were retrospectively identified. Clinical data and SBE findings were extracted from the medical record. Recurrence of OGIB during follow-up through 2012 was assessed by a combination of chart review and telephone interviews. RESULTS: One hundred and forty-seven patients were included in the study. The overall diagnostic yield of SBE was 64.6% (95/147 patients). Findings of SBE included vascular lesions (VLs, 53.7%), small bowel neoplasm (2.7%), inflammatory lesions (4.8%), and normal SBE (35.4%). One hundred and ten patients (56.4% female, mean age 70.6±11.3 years) were followed for an average 23.9 months after initial SBE. During follow-up, OGIB recurred in 39.5% of patients in whom a source of OGIB was identified on SBE and 55.9% of patients with normal findings on SBE. OGIB recurred in 47.6% of patients in whom small bowel VLs were treated endoscopically. None of the 13 patients in whom a non-VL lesion was identified as the source of bleeding on SBE experienced recurrent bleeding (p=0.019). CONCLUSIONS: SBE is a safe and valuable method for managing patients with OGIB. More than 50% of patients experienced no recurrent bleeding during 2 years of follow-up after SBE. The long-term management of OGIB due to small bowel VLs remains challenging.
BACKGROUND: Limited data exists on the long-term outcomes of patients with obscure gastrointestinal bleeding (OGIB) following single-balloon enteroscopy (SBE). AIM: To examine the long-term outcomes of patients undergoing SBE for OGIB. METHODS: Consecutive patients undergoing SBE for OGIB at a tertiary care center between 2008 and 2010 were retrospectively identified. Clinical data and SBE findings were extracted from the medical record. Recurrence of OGIB during follow-up through 2012 was assessed by a combination of chart review and telephone interviews. RESULTS: One hundred and forty-seven patients were included in the study. The overall diagnostic yield of SBE was 64.6% (95/147 patients). Findings of SBE included vascular lesions (VLs, 53.7%), small bowel neoplasm (2.7%), inflammatory lesions (4.8%), and normal SBE (35.4%). One hundred and ten patients (56.4% female, mean age 70.6±11.3 years) were followed for an average 23.9 months after initial SBE. During follow-up, OGIB recurred in 39.5% of patients in whom a source of OGIB was identified on SBE and 55.9% of patients with normal findings on SBE. OGIB recurred in 47.6% of patients in whom small bowel VLs were treated endoscopically. None of the 13 patients in whom a non-VL lesion was identified as the source of bleeding on SBE experienced recurrent bleeding (p=0.019). CONCLUSIONS: SBE is a safe and valuable method for managing patients with OGIB. More than 50% of patients experienced no recurrent bleeding during 2 years of follow-up after SBE. The long-term management of OGIB due to small bowel VLs remains challenging.
Authors: Christopher W Teshima; Ernst J Kuipers; Sander Veldhuyzen van Zanten; Peter B F Mensink Journal: J Gastroenterol Hepatol Date: 2011-05 Impact factor: 4.029
Authors: E Samaha; G Rahmi; B Landi; C Lorenceau-Savale; G Malamut; J-M Canard; F Bloch; R Jian; G Chatellier; C Cellier Journal: Am J Gastroenterol Date: 2011-09-27 Impact factor: 10.864
Authors: D Domagk; P Mensink; H Aktas; P Lenz; T Meister; A Luegering; H Ullerich; L Aabakken; A Heinecke; W Domschke; E Kuipers; M Bretthauer Journal: Endoscopy Date: 2011-03-07 Impact factor: 10.093
Authors: Jaya R Agrawal; Anne C Travis; Koenraad J Mortele; Stuart G Silverman; Rie Maurer; Sarathchandra I Reddy; John R Saltzman Journal: J Gastroenterol Hepatol Date: 2012-04 Impact factor: 4.029
Authors: Ashley H Davis-Yadley; Seth Lipka; Andrea C Rodriguez; Kirbylee K Nelson; Vignesh Doraiswamy; Roshanak Rabbanifard; Ambuj Kumar; Patrick G Brady Journal: Therap Adv Gastroenterol Date: 2016-03 Impact factor: 4.409
Authors: Kirbylee K Nelson; Seth Lipka; Ashley H Davis-Yadley; Andrea C Rodriguez; Vignesh Doraiswamy; Roshanak Rabbanifard; Ambuj Kumar; Patrick G Brady Journal: Endosc Int Open Date: 2016-06-29